TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Sponsor: CG Oncology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 325 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06567743 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06567743 Rescue Dossier →